Accès gratuit
Cet article est une note pour : [cet article]

Med Sci (Paris)
Volume 29, Numéro 1, Janvier 2013
Page(s) 57 - 63
Section Traduction
Publié en ligne 8 octobre 2014
  1. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-Cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982 ; 306 : 517–522. [CrossRef] [PubMed]
  2. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012 ; 12 : 298–306. [CrossRef] [PubMed]
  3. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007 ; 13 : 5133–5143. [CrossRef] [PubMed]
  4. Stagg J, Sharkey J, Pommey S, et al. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc Natl Acad Sci USA 2008 ; 105 : 16254–16259. [CrossRef]
  5. Park SG, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010 ; 18 : 160–170. [CrossRef] [PubMed]
  6. Sala A, Gresser I, Chassoux D, et al. Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action. Cancer Res 1992 ; 52 : 2880–2889. [PubMed]
  7. Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010 ; 116 : 926–934. [CrossRef] [PubMed]
  8. Eibler N, Ruf P, Mysliwietz, et al. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res 2012 [Epub ahead of print].
  9. Cartron G, Watier H, Golay J, Solal-Celigny P. from the bench to the bedside: ways to improve rituximab efficacy. Blood 2004 ; 104 : 2635–2642. [CrossRef] [PubMed]
  10. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 ; 363 : 711–723. [CrossRef] [PubMed]
  11. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008 ; 14 : 3044–3051. [CrossRef] [PubMed]
  12. Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011 ; 108 : 7142–7147. [CrossRef]
  13. Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012 ; 122 : 1066–1075. [CrossRef] [PubMed]
  14. Houot R, Goldstein MJ, Korht HE, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009 ; 114 : 3431–3438. [CrossRef] [PubMed]
  15. Yu P, Steel JC, Zhang M, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc. Natl. Acad. Sci. USA 2012 ; 109 : 6187–6192. [CrossRef]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.